It is likely that a proper balance in the activity of IP6Ks is required to modulate cell motility, preventing cancer transformation; a valid pharmacological endeavor would aim at modulating, rather than abolishing, IP6K-dependent IP7 synthesis. Here, PPIP5K1 is linked to cancer.